Collegium Pharmaceutical, Inc. Proceeds from Sale of Debt Securities, Available-for-sale
Collegium Pharmaceutical, Inc. (COLL) reported Proceeds from Sale of Debt Securities, Available-for-sale of $151.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00.
- Collegium Pharmaceutical, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-06-30 was $0.00.
- Collegium Pharmaceutical, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-03-31 was $0.00.
- Collegium Pharmaceutical, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2023 was $0.00.
| Period end | Proceeds from Sale of Debt Securities, Available-for-sale 3 month | Proceeds from Sale of Debt Securities, Available-for-sale 6 month | Proceeds from Sale of Debt Securities, Available-for-sale 9 month | Proceeds from Sale of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $151.81M 10-Q · filed 2026-08-06 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $0.00 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |